← Back to Search

Vascular Assessment for Peripheral Arterial Disease

N/A

Waitlist Available

Led By Joshua Beckman, MD

Research Sponsored by Vanderbilt University Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Inclusion/

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline

Awards & highlights

Study Summary

This trial is testing whether two types of vessel abnormalities working together cause worse leg function and walking.

Eligible Conditions

Peripheral Arterial Disease

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ change from baseline to 12 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~change from baseline to 12 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

C3/C5 acylcarnitine levels in PAD surgical bypass group

C3/C5acylcarnitine levels in PAD exercise group after 12 weeks

C3/C5acylcarnitine levels in healthy control subjects.

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Peripheral Artery Disease (PAD) with Supervised ExerciseExperimental Treatment2 Interventions

Subjects will be referred for supervised exercise therapy. Subjects will have 3 visits per week for 12 weeks. Each visit will include a minimum of 30 to 40 minutes of exercise to improve ambulation with a certified trainer.

Group II: Healthy SubjectsExperimental Treatment1 Intervention

Group III: PAD Subjects Who Undergo Revascularization of the LegActive Control1 Intervention

This group of subjects are receiving leg revascularization as part of standard of care.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Vascular Assessment

2018

N/A

~80

Supervised Exercise

2017

Completed Phase 1

~340

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Vanderbilt University Medical CenterLead Sponsor

856 Previous Clinical Trials

672,112 Total Patients Enrolled

3 Trials studying Peripheral Arterial Disease

727 Patients Enrolled for Peripheral Arterial Disease

American Heart AssociationOTHER

324 Previous Clinical Trials

4,933,698 Total Patients Enrolled

9 Trials studying Peripheral Arterial Disease

748 Patients Enrolled for Peripheral Arterial Disease

Joshua Beckman, MDPrincipal Investigator - Vanderbilt University Medical Center

Vanderbilt University Medical Center

New York University School Of Medicine (Medical School)

Ny And Presby Hospital (Residency)

3 Previous Clinical Trials

117 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is recruitment for this clinical trial still in progress?

"Affirmative. Evidence hosted on clinicaltrials.gov substantiates that this medical experiment is actively recruiting participants, after being first posted on May 22nd 2018 and last updated September 16th 2022. The study requires 100 people at a single location for completion."

Answered by AI

How many participants are being recruited for this research project?

"Yes, the trial is currently enrolling. According to clinicaltrials.gov, which has most recently been updated on September 16th 2022, this research intends to include 100 participants at 1 particular location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

The Impact of Branched-Chain Amino Acid Metabolism on Limb Dysfunction in PAD

Joshua Beckman 2018. "The Impact of Branched-Chain Amino Acid Metabolism on Limb Dysfunction in PAD". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03490968.